Business Description
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd
ISIN : CNE100002WP3
Share Class Description:
SHSE:603707: Class ACompare
Compare
Traded in other countries / regions
603707.China IPO Date
2017-07-19Description
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd is a China-based company engaged in the research and development, import and export of medicines and health products. The main products of the company are Heparin sodium and low molecular weight heparin. Geographically, the business activities are carried out through China and it exports the product mainly to the European and American countries.
Financial Strength
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.85 | |||||
| Equity-to-Asset | 0.67 | |||||
| Debt-to-Equity | 0.37 | |||||
| Debt-to-EBITDA | -4.92 | |||||
| Interest Coverage | 11.19 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 5.89 | |||||
| Beneish M-Score | -2.68 | |||||
| WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 0.9 | |||||
| 3-Year Book Growth Rate | 15 | |||||
| Future 3-5Y Total Revenue Growth Rate | 21.4 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 63.9 | |||||
| 9-Day RSI | 54.46 | |||||
| 14-Day RSI | 52.91 | |||||
| 6-1 Month Momentum % | 11.89 | |||||
| 12-1 Month Momentum % | -8.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 3.13 | |||||
| Quick Ratio | 1.51 | |||||
| Cash Ratio | 0.88 | |||||
| Days Inventory | 677.91 | |||||
| Days Sales Outstanding | 83.93 | |||||
| Days Payable | 89.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 0.68 | |||||
| Dividend Payout Ratio | 0.23 | |||||
| 3-Year Dividend Growth Rate | -20.7 | |||||
| Forward Dividend Yield % | 0.68 | |||||
| 5-Year Yield-on-Cost % | 1.5 | |||||
| 3-Year Average Share Buyback Ratio | -0.8 | |||||
| Shareholder Yield % | 3.36 |
Profitability Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 42.02 | |||||
| Operating Margin % | 22.07 | |||||
| Net Margin % | -10.91 | |||||
| FCF Margin % | 22 | |||||
| ROE % | -6.83 | |||||
| ROA % | -4.27 | |||||
| ROIC % | 9.57 | |||||
| ROC (Joel Greenblatt) % | -8.42 | |||||
| ROCE % | -6.8 | |||||
| Years of Profitability over Past 10-Year | 9 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 19.93 | |||||
| PE Ratio without NRI | 34.24 | |||||
| Shiller PE Ratio | 43 | |||||
| PS Ratio | 6.06 | |||||
| PB Ratio | 3.77 | |||||
| Price-to-Tangible-Book | 4.27 | |||||
| Price-to-Free-Cash-Flow | 27.3 | |||||
| Price-to-Operating-Cash-Flow | 15.45 | |||||
| EV-to-EBIT | -50.76 | |||||
| EV-to-EBITDA | -50.76 | |||||
| EV-to-Revenue | 6.13 | |||||
| EV-to-FCF | 28.31 | |||||
| Price-to-Projected-FCF | 4.35 | |||||
| Price-to-Graham-Number | 2.55 | |||||
| Price-to-Net-Current-Asset-Value | 6.22 | |||||
| Earnings Yield (Greenblatt) % | -1.97 | |||||
| FCF Yield % | 3.61 | |||||
| Forward Rate of Return (Yacktman) % | 18.04 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 3,877.478 | ||
| EPS (TTM) (Â¥) | -0.27 | ||
| Beta | 1.5 | ||
| Volatility % | 49.64 | ||
| 14-Day RSI | 52.91 | ||
| 14-Day ATR (Â¥) | 0.522856 | ||
| 20-Day SMA (Â¥) | 14.6665 | ||
| 12-1 Month Momentum % | -8.28 | ||
| 52-Week Range (Â¥) | 10.45 - 16.4 | ||
| Shares Outstanding (Mil) | 1,615.63 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd Stock Events
| Event | Date | Price(Â¥) | ||
|---|---|---|---|---|
| No Event Data | ||||
Nanjing King-Friend Biochemical Pharmaceutical Co Ltd Frequently Asked Questions
What is Nanjing King-Friend Biochemical Pharmaceutical Co Ltd(SHSE:603707)'s stock price today?
The current price of SHSE:603707 is ¥14.62. The 52 week high of SHSE:603707 is ¥16.40 and 52 week low is ¥10.45.
When is next earnings date of Nanjing King-Friend Biochemical Pharmaceutical Co Ltd(SHSE:603707)?
The next earnings date of Nanjing King-Friend Biochemical Pharmaceutical Co Ltd(SHSE:603707) is .
Does Nanjing King-Friend Biochemical Pharmaceutical Co Ltd(SHSE:603707) pay dividends? If so, how much?
The Dividend Yield %  of Nanjing King-Friend Biochemical Pharmaceutical Co Ltd(SHSE:603707) is 0.68% (As of Today), Highest Dividend Payout Ratio of Nanjing King-Friend Biochemical Pharmaceutical Co Ltd(SHSE:603707) was 0.36. The lowest was 0.14. And the median was 0.16. The  Forward Dividend Yield % of Nanjing King-Friend Biochemical Pharmaceutical Co Ltd(SHSE:603707) is 0.68%. For more information regarding to dividend, please check our Dividend Page.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers